TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$98 Million

Quanterix Corporation

Follow-on Offering

Bookrunner, August 2020

Quanterix Corporation

Quanterix Corporation (“Quanterix” or the “Company”) is a life sciences company that has developed a next generation, ultra- sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Company's platform enables customers to reliably detect protein biomarkers in extremely low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. It also allows researchers to define and validate the function of novel protein biomarkers that are only present in very low concentrations and have been discovered using technologies such as mass spectrometry. These capabilities provide the Company's customers with insight into the role of protein biomarkers in human health that has not been possible with other existing technologies and enable researchers to unlock unique insights into the continuum between health and disease. The Company is currently focusing its platform on protein detection and is also developing its Simoa technology to detect nucleic acids in biological samples.